Effect of single doses of SLV306, an inhibitor of both neutral endopeptidase and endothelin-converting enzyme, on pulmonary pressures in congestive heart failure☆
References (8)
- et al.
Endothelins are potent vasoconstrictors, and much more besides
Trends Pharmacol Sci
(2000) - et al.
Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure?
Int J Cardiol
(2002) - et al.
Neutral endopeptidase 24.11 inhibition may not exhibit beneficial hemodynamic effects in patients with congestive heart failure
Eur J Clin Pharmacol
(1996) SLV-306
Curr Opin Invest Drugs
(2003)
Cited by (38)
Neutral endopeptidase (neprilysin)
2023, Metalloenzymes: From Bench to BedsideThe endothelin system as target for therapeutic interventions in cardiovascular and renal disease
2020, Clinica Chimica ActaCitation Excerpt :However, limited data is present on the role of ECE therapy in patients with HF. There are less evidence that ECE (alone or in combination with a neutral endopeptidase [NEP] inhibitor) might improve hemodynamics in HF [51,170]. As a result of several studies with negative results, the interest in treatment with agents providing endothelin receptor antagonism for patients with HF has declined.
Current role of neprilysin inhibitors in hypertension and heart failure
2014, Pharmacology and TherapeuticsNew therapeutic options in heart failure. What's on the horizon? An overview
2013, International Journal of CardiologyCitation Excerpt :Evidence is limited in humans. ECE therapy [alone or in combination with a neutral endopeptidase (NEP) inhibitor] appears to improve hemodynamics, but clinical outcomes have not been evaluated [46,47]. Based on pre-clinical data suggesting benefits of combining an ACE inhibitor with an ECE–NEP inhibitor in heart failure [48], triple inhibitors of ECE, ACE, and NEP are also under development [49].
The dual endothelin converting enzyme/neutral endopeptidase inhibitor SLV-306 (daglutril), inhibits systemic conversion of big endothelin-1 in humans
2012, Life SciencesCitation Excerpt :Combined NEP and ECE inhibition, leading to augmented natriuretic peptide concentrations, coupled with reduced ET-1 synthesis is an attractive therapeutic strategy in a range of cardiovascular diseases. Following oral administration, SLV-306 (daglutril) is hydrolysed to the active metabolite KC-12615 (Dickstein et al., 2004), a new chemical entity which is a mixed enzyme inhibitor of both ECE and NEP. The inhibitor has not been extensively studied but in diabetic rats, SLV-306 has been shown to reduce proteinuria and urinary albumin excretion (Thöne-Reinke et al., 2004).
Current Landscape of Therapeutics for the Management of Hypertension-A Review
2024, Current Drug Delivery
- ☆
This study was supported by a grant from Solvay Pharmaceuticals, Weesp, The Netherlands.